Literature DB >> 6571714

Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies.

D Ferrero, S Pessano, G L Pagliardi, G Rovera.   

Abstract

The surface changes occurring in three acute myeloid leukemia cell lines (HL60, ML3, and KG1) induced to differentiate by a variety of agents (dimethylsulfoxide, retinoic acid, 12-O-tetradecanoylphorbol-13-acetate, and factors present in lymphocyte conditioned medium) were probed using monoclonal antibodies that are differentiation stage- and lineage-specific. In all cases, the differentiated phenotype was defective and varied with the inducing agent and the cell line used. HL60 proved to be the most sensitive to the effect of the inducers. Retinoic acid was better than DMSO, and TPA was better than the medium factors in the ability to induce granulocytic and monocytic differentiation, respectively, in HL60 cells. These findings indicate that the differentiation block in acute myeloid leukemias is heterogeneous and that each cell line has different phenotypic characteristics that are responsible for the extent of differentiation obtained with a given inducer. These results also suggest that the extent of the differentiation response in vitro may be improved by the use of more suitable inducers for each specific leukemic line.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571714

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.

Authors:  M R Bootcov; A R Bauskin; S M Valenzuela; A G Moore; M Bansal; X Y He; H P Zhang; M Donnellan; S Mahler; K Pryor; B J Walsh; R C Nicholson; W D Fairlie; S B Por; J M Robbins; S N Breit
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues.

Authors:  R D Huhn; M R Posner; S I Rayter; J G Foulkes; A R Frackelton
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

3.  Induction of the granulocyte-macrophage colony-stimulating factor (CSF) receptor by granulocyte CSF increases the differentiative options of a murine hematopoietic progenitor cell.

Authors:  B L Kreider; P D Phillips; M B Prystowsky; N Shirsat; J H Pierce; R Tushinski; G Rovera
Journal:  Mol Cell Biol       Date:  1990-09       Impact factor: 4.272

4.  Transient formation of DNA strand breaks during the induced differentiation of a human promyelocytic leukaemic cell line, HL-60.

Authors:  F Farzaneh; R Meldrum; S Shall
Journal:  Nucleic Acids Res       Date:  1987-04-24       Impact factor: 16.971

5.  cGMP-induced differentiation of the promyelocytic cell line HL-60.

Authors:  G R Boss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.

Authors:  R E Clark; S A Smith; A Jacobs
Journal:  J Clin Pathol       Date:  1987-06       Impact factor: 3.411

7.  Differentiation of human leukaemic cell lines and fresh leukaemia cells by low dose Ara-C: monitoring by expression of c-myc and c-fos oncogenes.

Authors:  A Pinto; V Attadia; R Rosati; G Colletta; R Cimino; A Colombatti
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

8.  Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Authors:  K D Sabbath; E D Ball; P Larcom; R B Davis; J D Griffin
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 9.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

Review 10.  Differentiation therapy revisited.

Authors:  Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2017-12-01       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.